Novo Nordisk A/S
NOVO-B
Rang în acțiuni
#107
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Preț acțiune
$39.74
Capitalizare de piață
$175.38B
Schimbare (1 zi)
1.28%
Schimbare (1 an)
-25.58%
Țară
DK
Tranzacționează Novo Nordisk A/S (NOVO-B)
Categorie
Healthcare
Venituri pentru Novo Nordisk A/S (NOVO-B)
Venituri în Dec 2025 TTM: $48.55B
Conform celor mai recente rapoarte financiare ale Novo Nordisk A/S, venitul actual al companiei (TTM) este $48.55B. În anul 2024, compania a avut un venit de $40.52B o creștere față de venitul din anul 2023, care a fost de $34.39B. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru Novo Nordisk A/S din 2001 până în 2026
Venituri la sfârșitul fiecărui an
| An | Venituri | Schimbă |
|---|---|---|
| 2026 (TTM) | $48.55B | 0.00% |
| 2025 | $48.55B | 19.82% |
| 2024 | $40.52B | 17.82% |
| 2023 | $34.39B | 35.02% |
| 2022 | $25.47B | 18.29% |
| 2021 | $21.53B | 3.33% |
| 2020 | $20.84B | 13.79% |
| 2019 | $18.31B | 6.63% |
| 2018 | $17.17B | -4.59% |
| 2017 | $18.00B | 13.46% |
| 2016 | $15.86B | 0.88% |
| 2015 | $15.73B | 8.89% |
| 2014 | $14.44B | -6.28% |
| 2013 | $15.41B | 11.69% |
| 2012 | $13.80B | 19.42% |
| 2011 | $11.55B | 6.01% |
| 2010 | $10.90B | 10.52% |
| 2009 | $9.86B | 15.53% |
| 2008 | $8.54B | 3.65% |
| 2007 | $8.24B | 20.44% |
| 2006 | $6.84B | 28.15% |
| 2005 | $5.34B | -0.14% |
| 2004 | $5.34B | 18.51% |
| 2003 | $4.51B | 27.01% |
| 2002 | $3.55B | 25.45% |
| 2001 | $2.83B | 0.00% |
Venituri pentru companii similare sau concurente
| Companie | Venituri | Diferență de venituri | Țara |
|---|---|---|---|
| $79.67B | 64.10% |
US
|
|
| $99.34B | 104.61% |
US
|
|
| $64.39B | 32.62% |
US
|
|
| $66.40B | 36.77% |
US
|
|
| $77.52B | 59.67% |
CH
|
